Drug intelligence / Profile preview

SKB394

Development stage: Unknown
Lead developer: Henan Cancer Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

SKB394 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell maturation antigen (BCMA), a protein highly expressed on the surface of malignant plasma cells in multiple myeloma. Developed by The Affiliated Cancer Hospital of Zhengzhou University, SKB394 involves the genetic modification of a patient's own T cells to express a CAR that recognizes and binds to BCMA, leading to the targeted destruction of myeloma cells. It is primarily being investigated for the treatment of patients with relapsed or refractory multiple myeloma who have failed standard therapies.

Other names: BCMA-targeted CAR-T cellsSKB394 CAR-TSKB-394 CAR-TSKB 394 CAR-T

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on SKB394.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKB394.

Explore the full profile